Psychiatr. praxi. 2026;27(1):6-11 | DOI: 10.36290/psy.2026.001

Mood stabilisers

doc. PharmDr. Jana Hroudová, Ph.D.1, 2, PharmDr. Alena Pilková, Ph.D.2, doc. MUDr. Lucie Kališová, Ph.D.3
1 Psychiatrická klinika, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze
2 Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze
3 Psychiatrické oddělení, Ústřední vojenská nemocnice, Praha

This article provides a comprehensive summary of mood stabilizers used in routine clinical psychiatric practice in the Czech Republic. These medications are used to reduce the risk of depressive or manic episodes in patients with bipolar or schizoaffective disorder. The article pays particular attention to lithium, covering its pharmacological profile, proven efficacy, and adverse effects associated with its administration. Additionally, sodium valproate, carbamazepine, and lamotrigine are described in detail from pharmacological and psychiatric perspectives. The article concludes with a summary of recommendations for clinical practice.

Keywords: mood stabilisers, thymoprophylaxis, lithium, valproic acid, carbamazepine, lamotrigine.

Accepted: March 12, 2026; Published: March 23, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hroudová J, Pilková A, Kališová L. Mood stabilisers. Psychiatr. praxi. 2026;27(1):6-11. doi: 10.36290/psy.2026.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 23.3.2027

    References

    1. Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed, (2013).
    2. Mohr P, Kopeček M. Klinická psychofarmakologie. 2024.
    3. Rybakowski JK. Mood Stabilizers of First and Second Generation. Brain Sci. 2023;13(5):741. Go to original source...
    4. Shorter E. The history of lithium therapy. Bipolar disorders. 2009;11 Suppl 2(Suppl 2):4-9. Go to original source... Go to PubMed...
    5. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349-52. Go to original source...
    6. Kessing LV, Bauer M, Nolen WA, et al. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar disorders. 2018. Go to original source...
    7. Gitlin M, Bauer M. Lithium: current state of the art and future directions. Int J Bipolar Disord. 2024;12(1):40. Go to original source...
    8. Bauer M, Gitlin M. The Essential Guide to Lithium Treatment. 2016. Go to original source...
    9. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta psychiatrica Scandinavica. 1999;100(6):406-17. Go to original source... Go to PubMed...
    10. Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of affective disorders. 2014;168:269-75. Go to original source... Go to PubMed...
    11. Tondo L, Vázquez GH, Baldessarini RJ. Prevention of suicidal behavior in bipolar disorder. Bipolar disorders. 2021;23(1):14-23. Go to original source...
    12. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ (Clinical research ed). 2013;346:f3646. Go to original source...
    13. Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology. 2010;62(1):43-9. Go to original source... Go to PubMed...
    14. Hajek T, Bauer M, Simhandl C, et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychological medicine. 2014;44(3):507-17. Go to original source... Go to PubMed...
    15. Sakrajda K, Rybakowski JK. The Mechanisms of Lithium Action: The Old and New Findings. Pharmaceuticals (Basel). 2025;18(4):467. Go to original source... Go to PubMed...
    16. Shen Y, Zhao M, Zhao P, et al. Molecular mechanisms and therapeutic potential of lithium in Alzheimer's disease: repurposing an old class of drugs. Front Pharmacol. 2024;15:1408462. Go to original source... Go to PubMed...
    17. Scott J, Etain B, Manchia M, et al. An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. Bipolar Disord. 2020;22(3):255-65. Go to original source... Go to PubMed...
    18. Scott K, Khayachi A, Alda M,et al. Prediction of Treatment Outcome in Bipolar Disorder: When Can We Expect Clinical Relevance? Biol Psychiatry. 2025;98(4):285-92. Go to original source... Go to PubMed...
    19. Shulman KI, Almeida OP, Herrmann N, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: An ISBD task force report. Bipolar Disord. 2019;21(2):117-23. Go to original source...
    20. Xu N, Huggon B, Saunders KEA. Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment. CNS Drugs. 2020;34(1):29-46. Go to original source... Go to PubMed...
    21. Koch J, Launio M, Williams AM. Extrapyramidal side effects with nonantipsychotic medications. Ment Health Clin. 2024;14(4):233-5. Go to original source...
    22. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1):27. Go to original source... Go to PubMed...
    23. Kovacs Z, Vestergaard P, Licht RW, et al. Lithium induced hypercalcemia: an expert opinion and management algorithm. Int J Bipolar Disord. 2022;10(1):34. Go to original source... Go to PubMed...
    24. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. Journal of psychopharmacology (Oxford, England). 2006;20(3):347-55. Go to original source...
    25. Finley PR. Drug Interactions with Lithium: An Update. Clin Pharmacokinet. 2016;55(8):925-41. Go to original source...
    26. Armstrong GP. Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications. Am J Case Rep. 2020;21:e923311. Go to original source...
    27. Verdoux H, Quiles C, de Leon J. Risks and benefits of clozapine and lithium co-prescribing: A systematic review and expert recommendations. Schizophr Res. 2024;268:233-42. Go to original source... Go to PubMed...
    28. Databáze AISLP. aktuální SPC, stav k 1. 7. 2025.
    29. Huband N, Ferriter M, Nathan R, et al. Antiepileptics for aggression and associated impulsivity. The Cochrane database of systematic reviews. 2010;2010(2):Cd003499. Go to original source... Go to PubMed...
    30. García-Trevijano-Cabetas M, Poveda-Escolar A, Cordero-Guijarro A, et al. Comparison of four valproic acid free fraction determination methods used in clinical practice. Farm Hosp. 2022;46(2):80-3.
    31. Gopaul SV, Farrell K, Abbott FS. Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos. 2000;28(7):823-32. Go to original source...
    32. Wahab A, Iqbal A. Black-Box Warnings of Antiseizure Medications: What is Inside the Box? Pharmaceut Med. 2023;37(3):233-50. Go to original source...
    33. Rahman M, Awosika AO, Nguyen H. Valproic Acid. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC. 2025.
    34. Smith V, Brown N. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. Arch Dis Child Educ Pract Ed. 2014;99(5):198. Go to original source... Go to PubMed...
    35. Harden CL. In utero valproate exposure and autism: long suspected, finally proven. Epilepsy Curr. 2013;13(6):282-4. Go to original source... Go to PubMed...
    36. Andrade C, Varadharajan N, Bascarane S, et al. Gestational Exposure to Valproate and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring: Systematic Review and Meta-Analysis. Acta psychiatrica Scandinavica. 2025;151(6):668-79. Go to original source... Go to PubMed...
    37. Patel AR, Nagalli S. Valproate Toxicity. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.
    38. Chen IL, Lee CH, Hsiao SC, et al. Interactions between carbapenems and valproic acid among the patients in the intensive care units. J Crit Care. 2021;62:151-6. Go to original source... Go to PubMed...
    39. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409-31. Go to original source... Go to PubMed...
    40. Malik S, Lally J, Ajnakina O, et al. Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophr Res. 2018;195:267-73. Go to original source...
    41. Hennings JM. Mood Stabilizers: Carbamazepine. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2022. p. 1523-36. Go to original source...
    42. Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 1983;140(12):1602-4. Go to original source... Go to PubMed...
    43. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. Psychiatry Res. 1987;21(1):71-83. Go to original source...
    44. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology. 2000;42 Suppl 1:2-10. Go to original source... Go to PubMed...
    45. Ambrósio AF, Soares-Da-Silva P, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27(1-2):121-30. Go to original source... Go to PubMed...
    46. Maan JS, Duong TVH, Saadabadi A. Carbamazepine. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.
    47. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. Go to original source... Go to PubMed...
    48. Goldberg JF. Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders? An Evidence-Based Appraisal. The Journal of clinical psychiatry. 2024;85(1). Go to original source... Go to PubMed...
    49. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):e1. Go to original source... Go to PubMed...
    50. Suleman N, Ozdemirli M, Weisman D. Lamotrigine-associated hemophagocytic lymphohistiocytosis. BMJ Case Rep. 2021;14(1). Go to original source... Go to PubMed...
    51. Grundmann M, Koristkova B, Brozmanova H, et al. Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients. Therapeutic drug monitoring. 2017;39(5):543-9. Go to original source... Go to PubMed...
    52. Češková E, Šilhán P, Kacířová I, et al. Terapeutické monitorování léčiv v psychiatrii. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP [Internet]. 2018.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.